Delhi HC: Glenmark can't sell diabetes drug Zita, Zita-Met

Written By Unknown on Jumat, 20 Maret 2015 | 21.03

US pharmaceutical major Merck Sharp and Dohme (MSD) had filed an appeal before the Delhi High Court challenging its single Bench order refusing to grant interim relief to it on a patent row against Indian firm Glenmark Pharmaceuticals.

The Delhi High Court restrains  Glenmark from manufacturing and marketing its anti-diabetes drugs Zita and Zita-Met.

HC says Glenmark has prima facie infringed Merck Sharp and Dohme's patent in anti-diabetes drug.

Glenmark shares ended down Rs. 21.80 or 2.56 percent at Rs. 830.90 on the BSE.

US pharmaceutical major Merck Sharp and Dohme (MSD) had filed an appeal before the Delhi High Court challenging its single Bench order refusing to grant interim relief to it on a patent row against Indian firm Glenmark Pharmaceuticals.

The US-based company filed the appeal before the Bench of justices Sanjay Kishan Kaul and Indermeet Kaur against the April 5, 2013 order of the single Bench which had dismissed its plea for restraining Glenmark Pharmaceuticals from manufacturing and marketing anti-diabetes drugs Zita and Zita-Met.

The single judge had in an interim order dismissed MSD's plea but had directed Glenmark Pharmaceuticals to "diligently maintain accounts of the manufacturing/production and sales of the infringing products" and to file the same before it.

The order had come on a petition by MSD which had alleged that the Indian pharma company has violated its intellectual property right over its anti-diabetes medicines, Januvia and Janumet, by coming in the market with their own drugs containing the same salts.

However, the High Court has kept the main petition of MSD pending for adjudication.

The US firm had sought the High Court's order to restrain the Mumbai-based firm from manufacturing and sale of drugs Zita and Zita-Met for treatment of Type-2 diabetes.

The US firm had said it had invented 'Sitagliptin' salt, used in the anti-diabetes drugs, and has patent over the molecule.

Glenmark stock price

On March 20, 2015, Glenmark Pharma closed at Rs 830.90, down Rs 21.8, or 2.56 percent. The 52-week high of the share was Rs 879.05 and the 52-week low was Rs 546.60.


The company's trailing 12-month (TTM) EPS was at Rs 18.02 per share as per the quarter ended December 2014. The stock's price-to-earnings (P/E) ratio was 46.11. The latest book value of the company is Rs 107.12 per share. At current value, the price-to-book value of the company is 7.76.


Anda sedang membaca artikel tentang

Delhi HC: Glenmark can't sell diabetes drug Zita, Zita-Met

Dengan url

http://kebugaranhidup.blogspot.com/2015/03/delhi-hc-glenmark-cant-sell-diabetes.html

Anda boleh menyebar luaskannya atau mengcopy paste-nya

Delhi HC: Glenmark can't sell diabetes drug Zita, Zita-Met

namun jangan lupa untuk meletakkan link

Delhi HC: Glenmark can't sell diabetes drug Zita, Zita-Met

sebagai sumbernya

0 komentar:

Posting Komentar

techieblogger.com Techie Blogger Techie Blogger